肝内胆管癌预后评分MEGNA的开发与外部验证
该研究基于加州癌症登记处2004—2011年数据及住院数据库,纳入275例接受肝切除的肝内胆管癌患者,比较局限于肝内、小(<7 cm)且单发(ISS)与肝外侵犯、大(≥7 cm)且多发(ELM)肿瘤的围术期结局,并构建MEGNA预后评分。多因素Cox模型显示多发、肝外侵犯、分级、淋巴结阳性及年龄>60岁与更差总生存独立相关。MEGNA评分的预后区分度优于AJCC第6版和第7版分期系统。
要点
- MEGNA评分由多发、肝外侵犯、分级、淋巴结阳性、年龄>60岁构成。
- ISS与ELM组总体并发症率(34.5% vs 27.2%,P=.19)和死亡率(7.2% vs 4.4%,P=.32)无显著差异。
- MEGNA预后区分指数0.21(95%CI 0.11-0.33),优于AJCC第6版(0.17)和第7版(0.18)。
核心结论
- MEGNA预后评分较现有分期系统能更准确、更优地估计肝切除术后患者生存。
- 大且多发或伴邻近器官受累的ICC,其围术期并发症率和死亡率与ISS肿瘤无显著差异。
研究设计与样本
- 当代队列研究,合并加州癌症登记处(2004-01-01至2011-12-31)与Office of Statewide Health Planning and Development住院数据库数据。
- 纳入275例接受肝切除的肝内胆管癌患者:男性123例(44.7%),女性152例(55.3%),中位年龄65岁(IQR 55-72)。
- 外部验证使用美国国家癌症研究所SEER数据库独立数据集(2004-01-01至2013-12-31)。
- 主要结局为肝切除术后患者总生存。
主要发现
- ISS组总体并发症48例(34.5%),ELM组37例(27.2%),P=.19。
- ISS组死亡率10例(7.2%),ELM组6例(4.4%),P=.32。
- 多因素Cox比例风险模型显示多发、肝外侵犯、分级、淋巴结阳性及年龄>60岁与更差总生存独立相关。
- MEGNA预后区分/判别指数为0.21(95%CI 0.11-0.33),AJCC第6版为0.17(95%CI 0.09-0.29),第7版为0.18(95%CI 0.08-0.30)。
关键数值与推荐
- MEGNA预后评分包含变量:多发、肝外侵犯、分级、淋巴结阳性、年龄>60岁。
- MEGNA预后区分/判别指数0.21(95%CI 0.11-0.33)优于AJCC第6版0.17(95%CI 0.09-0.29)和第7版0.18(95%CI 0.08-0.30)。
- ISS与ELM组总体并发症率(34.5% vs 27.2%,P=.19)和死亡率(7.2% vs 4.4%,P=.32)无显著差异。
临床怎么用
- 对接受肝切除的肝内胆管癌患者,可用MEGNA评分辅助术后生存风险评估与分层。
- 对于大且多发或伴邻近器官受累的ICC,不应仅凭肿瘤特征预判围术期并发症或死亡风险更高。
- MEGNA评分可作为现有AJCC分期系统之外的补充预后工具。
局限性
- 研究为基于登记数据库的回顾性队列分析,可能存在选择偏倚和未测量混杂。
- MEGNA评分的预后区分度提升幅度有限,外部验证仅使用SEER数据库。
- 原文未报告MEGNA评分的具体分值赋权、风险分组截断值及校准度指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In patients with intrahepatic cholangiocarcinoma (ICC), the oncologic benefit of surgery and perioperative outcomes for large multifocal tumors or tumors with contiguous organ involvement remain to be defined. OBJECTIVES: To develop and externally validate a simplified prognostic score for ICC and to determine perioperative outcomes for large multifocal ICCs or tumors with contiguous organ involvement. DESIGN, SETTING, AND PARTICIPANTS: This study of a contemporary cohort merged data from the California Cancer Registry (January 1, 2004, through December 31, 2011) and the Office of Statewide Health Planning and Development inpatient database. Clinicopathologic variables were compared between tumors that were intrahepatic, small (<7 cm), and solitary (ISS) and those that had extrahepatic extension and were large (≥7 cm) and multifocal (ELM). External validation of the prognostic model was performed using an independent data set from the National Cancer Institute's Surveillance, Epidemiology, and End Results database from January 1, 2004, through December 31, 2013. MAIN OUTCOMES AND MEASURES: Patient overall survival after hepatectomy. RESULTS: A total of 275 patients (123 men [44.7%] and 152 women [55.3%]; median [interquartile range] age, 65 [55-72] years) met the inclusion criteria. No significant differences in overall complication rate (ISS, 48 [34.5%]; ELM, 37 [27.2%]; P = .19) and mortality rate (ISS, 10 [7.2%]; ELM, 6 [4.4%]; P = .32) were found. A multivariate Cox proportional hazards model demonstrated that multifocality, extrahepatic extension, grade, node positivity, and age greater than 60 years are independently associated with worse overall survival. These variables were used to develop the MEGNA prognostic score. The prognostic separation/discrimination index was improved with the MEGNA prognostic score (0.21; 95% CI, 0.11-0.33) compared with the staging systems of the American Joint Committee on Cancer sixth (0.17; 95% CI, 0.09-0.29) and seventh (0.18; 95% CI, 0.08-0.30) editions. CONCLUSIONS AND RELEVANCE: The MEGNA prognostic score allows more accurate and superior estimation of patient survival after hepatectomy compared with current staging systems.
引用
- Raoof M, Dumitra S, Ituarte PHG, et al. Development and Validation of a Prognostic Score for Intrahepatic Cholangiocarcinoma. JAMA Surg. 2017. PMID: 28297009. doi:10.1001/jamasurg.2017.0117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。